Astrazeneca

Career in AstraZeneca as Business Performance Lead

Global Technology Centre, Chennai is being established to provide high quality, scalable, cost effective IT services to the AstraZeneca global IT community. With a large pool of highly talented IT staff joining the centre in 2015, the centre will be very strategic in enabling AstraZeneca IT to achieve its overall objectives.  The leadership team of Chennai GTC (consisting of the AstraZeneca Chennai Site Lead, Tower Leads and Business Performance Lead) will focus on enabling the workforce to meet global organisational objectives of AstraZeneca IT - including ensuring high levels of service quality and delivery, as well as creating a Great Place to Work at AstraZeneca Chennai.  The Business Performance lead for Chennai GTC will be accountable to develop the strategy and measures to enable the Chennai centre to achieve its objectives in terms of quality, speed, efficiency, and service levels.

Post: Business Performance Lead

AstraZeneca receives CRL from US FDA for sodium zirconium cyclosilicate (ZS-9)

  • Posted on: 28 May 2016
  • By: Shalini.Sharma

AstraZeneca announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca.

US FDA grants orphan drug status to selumetinib

  • Posted on: 13 May 2016
  • By: Shalini.Sharma

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC). AstraZeneca acquired exclusive worldwide rights to selumetinib from Array BioPharma Inc. in 2003.

AstraZeneca fulfill deal of respiratory business of Takeda Pharma

  • Posted on: 5 May 2016
  • By: Shalini.Sharma

AstraZeneca has fulfilled the deal of the core respiratory business of Takeda Pharmaceutical Company Limited. The agreement, announced in December 2015.  Agreement includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca marketed Daliresp in the US in the first quarter of 2015.

AstraZeneca enters into US licensing agreement with Ironwood Pharmaceuticals for lesinurad

  • Posted on: 27 April 2016
  • By: Shalini.Sharma

AstraZeneca announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA)in December 2015, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of hyperuricemia associated with uncontrolled gout.

Bevespi Aerosphere™ approved by the US FDA for patients with COPD

  • Posted on: 27 April 2016
  • By: Shalini.Sharma

Astrazeneca announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

AstraZeneca launches integrated genomics approach to transform drug discovery and development

  • Posted on: 25 April 2016
  • By: Shalini.Sharma

AstraZeneca and its global biologics research and development arm, MedImmune, announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline.

AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease

  • Posted on: 12 April 2016
  • By: Shalini.Sharma

AstraZeneca and Eli Lilly and Company announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial.

Pages